BACKGROUND: Opsoclonus-myoclonus-ataxia (OMA) is a paraneoplastic syndrome that occurs in about 2-3% of all cases of neuroblastoma. The histopathologic characteristics of neuroblastoma tumors associated with this syndrome were evaluated in a series of cases and controls. PROCEDURE: Pathology slides from a total of 54 neuroblastoma tumors were reviewed blindly. They included 13 tumors associated with opsoclonus-myoclonus and 41 age- and stage-matched controls. All tumors were classified into either the favorable (FH) or unfavorable histology (UH) group according to the International Neuroblastoma Pathology Classification (the Shimada system). Grade of lymphocytic infiltration was evaluated and presence or absence of lymphoid follicles was recorded in the individual tumor tissues. RESULTS: Twelve of 13 cases with opsoclonus-myoclonus were in the FH group. Twelve of 13 cases had diffuse (found in every section prepared from the multiple portions of the primary tumor) and extensive (occupying more than 50% of a single of multiple microscopic fields with x 100 magnification) lymphocytic infiltration with lymphoid follicles. Of the 41 control cases (27 FH and 14 UH tumors), 18 had focal areas of lymphocytic infiltration and six showed lymphoid follicles, but none had diffuse or extensive infiltration in their primary tumors. CONCLUSIONS: Diffuse and extensive lymphocytic infiltration with lymphoid follicles is a characteristic histologic feature of neuroblastic tumors with opsoclonus-myoclonus. This observation suggests an immune-mediated mechanism for this rare paraneoplastic syndrome. Copyright 2001 Wiley-Liss, Inc.
BACKGROUND:Opsoclonus-myoclonus-ataxia (OMA) is a paraneoplastic syndrome that occurs in about 2-3% of all cases of neuroblastoma. The histopathologic characteristics of neuroblastoma tumors associated with this syndrome were evaluated in a series of cases and controls. PROCEDURE: Pathology slides from a total of 54 neuroblastoma tumors were reviewed blindly. They included 13 tumors associated with opsoclonus-myoclonus and 41 age- and stage-matched controls. All tumors were classified into either the favorable (FH) or unfavorable histology (UH) group according to the International Neuroblastoma Pathology Classification (the Shimada system). Grade of lymphocytic infiltration was evaluated and presence or absence of lymphoid follicles was recorded in the individual tumor tissues. RESULTS: Twelve of 13 cases with opsoclonus-myoclonus were in the FH group. Twelve of 13 cases had diffuse (found in every section prepared from the multiple portions of the primary tumor) and extensive (occupying more than 50% of a single of multiple microscopic fields with x 100 magnification) lymphocytic infiltration with lymphoid follicles. Of the 41 control cases (27 FH and 14 UH tumors), 18 had focal areas of lymphocytic infiltration and six showed lymphoid follicles, but none had diffuse or extensive infiltration in their primary tumors. CONCLUSIONS: Diffuse and extensive lymphocytic infiltration with lymphoid follicles is a characteristic histologic feature of neuroblastic tumors with opsoclonus-myoclonus. This observation suggests an immune-mediated mechanism for this rare paraneoplastic syndrome. Copyright 2001 Wiley-Liss, Inc.
Authors: Dominique Van Diest; Hendrik De Raeve; Jozef Claes; Paul M Parizel; Dirk De Ridder; Patrick Cras Journal: J Neurol Date: 2008-02-04 Impact factor: 4.849
Authors: Claudio Gambini; Massimo Conte; Gabriella Bernini; Paola Angelini; Andrea Pession; Paolo Paolucci; Alberto Donfrancesco; Edvige Veneselli; Katia Mazzocco; Gian Paolo Tonini; Lizzia Raffaghello; Carlo Dominici; Adriana Morando; Francesca Negri; Anna Favre; Bruno De Bernardi; Vito Pistoia Journal: Virchows Arch Date: 2003-04-23 Impact factor: 4.064
Authors: Julian P Layer; Marie T Kronmüller; Thomas Quast; Debby van den Boorn-Konijnenberg; Maike Effern; Daniel Hinze; Kristina Althoff; Alexander Schramm; Frank Westermann; Martin Peifer; Gunther Hartmann; Thomas Tüting; Waldemar Kolanus; Matthias Fischer; Johannes Schulte; Michael Hölzel Journal: Oncoimmunology Date: 2017-04-28 Impact factor: 8.110
Authors: Ana P Berbegall; Eva Villamón; Irene Tadeo; Tommy Martinsson; Adela Cañete; Victoria Castel; Samuel Navarro; Rosa Noguera Journal: Neoplasia Date: 2014-06 Impact factor: 5.715